Search 

We are focused on Valley Fever, an orphan disease that kills 150 people a year. Thousands are taking drugs for life, and many others have no effective drug therapy options. Nikkomycin-Z is a new, first in class antifungal ready for Phase II testing. Teliable animal models suggest NikZ will be effective. 

With our guidance, the NIH is funding two Phase II trials starting about late 2015. We would like to run a third, sweet-spot-of-market trial as soon as we secure funding. Our Chief Medical Officer is lead author on an NIH study on standard of care drugs for this disease. We plan to try NikZ under a simlar protocol as soon as we secure support. 

Valley Fever Solutions has made our API at pilot scale. The process is robust and repeatable. We are ready to make a large batch as soon as we secure funding. We expect the proof of concept trial can reach at least early readout within 18 months of funding. This can be achieved for less than $10M.

Ventac Partners is a dedicated life science investment and consulting firm with offices in Europe, USA and Asia. Ventac Partners has a strong track record in founding new innovative companies, fund raising and supporting M&A transactions.

All partners are experienced and hands-on life science entrepreneurs with proven track-record in successfully starting, funding, growing and expanding international life science companies.

VC fund focusing on investments in Switzerland and surounding areas

Vital Venture Capital, founded in 2007, is a venture capital firm with offices in: Simsbury, CT; Bethesda, MD; Philadelphia, PA; Naples, FL; and Lincolnshire, IL. The firm focuses on B2B, SaaS software, medical devices, and diagnostics. The firm seeks opportunities that provide some degree of investment loss protection through strong intellectual property. The firm’s target investment size is $1-3M for each portfolio company spread over 1-3 rounds. The firm invests in companies that are based in the US. The firm is actively seeking new investment opportunities.

Our clients are early-stage biotechnology, medical device, diagnostics and pharmaceutical service companies. When we begin working with a client they are frequently looking to complete proof-of-concept studies, secure intellectual property and other critical preliminary tasks. Typically we raise the first round ($1 - $5 million of capital) needed to accomplish these milestones, usually, but not always from angel investors. After key milestones have been achieved using that money, we generally follow by raising a second round of $5-20 million, usually institutional money, for development and growth

By working this way, we increase our clients' success rate raising capital and building their companies and the returns to the investors we bring into those companies. We have raised over $80 million in early stage funding for our clients (in Seed, Series A and Series B rounds) and delivered realized returns, so far, over $500 million—a realized return to date of over 6X—to the investors who provided that early stage capital, with a number of the companies still driving towards an exit that may increase that figure. Realized (cash-on-cash) internal rates of return for a hypothetical investor who participated in each round of financing offered by WG&A to date exceeds 65% annually.

Wellington Partners is a venture capital firm based in Munich, Germany, with an additional office in Zurich, Switzerland. The firm specializes in early-stage and growth capital investments in the Technology and Life Sciences sector. The firm has approximately €800M AUM and is currently investing out of a €100M fund for Life Science companies. Depending on the stage of the company, the firm can allocate up to €10M over the life of the investment. The firm can also lead or co-lead financing rounds of up to €30M or higher with syndicates. The firm focuses on European companies but will consider US-based companies with activities in Europe. The firm is actively seeking new investment opportunities.

WuXi Venture Fund is the corporate venture arm of WuXi AppTec, a multinational CRO based in Shanghai China with multiple offices across China and the United States. The fund makes equity investments into technology and life science companies to enhance or leverage WuXi AppTec's platform capabilities. The investment size will be varied based on a case-by-case basis. The firm invests in life science companies across the globe with an emphasis in China and the US.

Xeris is a clinical-stage pharmaceutical company developing patient-friendly injectable drugs for various indications with an initial focus on diabetes. The current paradigm for many injectable drugs is to design formulations for delivery in water-based systems.  However, the presence of water is problematic because it actively degrades many molecules often preventing drug products from being packaged for use as a “ready-to-use” solution.  Xeris' patented and patent-pending XeriSol™ and XeriJect™ formulation technologies are transformative in their elimination of water. By replacing water with non-water, bio-compatible carriers already used in other FDA-approved drugs, Xeris solves a number of problems adding significant value to existing injectable drugs and to new drugs in development.  This technology is already being validated with the development of a non-aqueous glucagon formulation that has shown 24 months of room-temperature stability in solution and very positive safety and efficacy in a Phase 2 clinical study. While this product and other glucagon products are being developed and $20M has been raised to support this development, Xeris is seeking to spinoff its earlier stage non-glucagon assets and obtain funding (both equity and non-dilutive) to support these projects.  More specifically, these projects include the development of a non-aqueous, auto-injectable diazepam to replace the current diazepam rectal gel for treatment of epileptic seizures and a non-aqueous, intradermal auto-injectable epinephrine to replace the current, antiquated EpiPen.